Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: An open-label, randomized-sequence, three-treatment, three-way crossover study
Clinical Therapeutics, 06/23/09
Cho SH et al. - The new formulation of rhEPO met the regulatory criteria for bioequivalence in these healthy Korean adult male volunteers. All formulations were generally well tolerated.
Related Articles
Extracts from The Cochrane Library: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
Otolaryngology Head and Neck Surgery, 10/12/09
Relevance Score: 87%
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
Haematologica, 10/21/09
Relevance Score: 85%
Removal of erythropoietin from anaemia trauma practice guideline does not increase red blood cell transfusions and decreases hospital utilization costs
Injury, 11/25/09
Relevance Score: 84%
School of Pharmacy Hopes to Close Clinical Gap for Elderly Blood Disorder
Internet Source, 11/05/09
Relevance Score: 84%
Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants
Journal of Pharmacology and Experimental Therapeutics, 10/09/09
Relevance Score: 84%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
Alimentary Pharmacology and Therapeutics, 12/10/09
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers
Current Medical Research and Opinion, 12/08/09
Sponsor
Article Search
Sponsor